Recall -- Firm Press Release
FDA posts press releases and other notices of recalls and market withdrawals from the firms involved as a service to consumers, the media, and other interested parties. FDA does not endorse either the product or the company.
CTV BEST GROUP Inc. Issues Voluntary Nationwide Recall of Dietary Supplements BEST SLIM 40 Pills LOT # 109400 EXP: Dec. 31, 2016 because of Potential Health Risk
FOR IMMEDIATE RELEASE - August 3, 2012 – Duluth, GA - CTV Best Group announced today that it is conducting a voluntary nationwide recall of all lots of a dietary supplement products distributed by the company under the names BEST SLIM 40 Pills to the consumer level. The product is distributed by CTV Best Group. Testing by the U.S. Food and Drug Administration (“FDA”) revealed the presence of “sibutramine” in Best Slim. CTV is recalling Best Slim as a precautionary measure.
"Sibutramine was a previously approved controlled substance for the treatment of obesity that was removed from the U.S. market in October 2010 for safety reasons, making this product an unapproved new drug.
Sibutramine is known to substantially increase blood pressure and/or pulse rate in some patients and may present a significant risk to patients with a history of coronary artery disease, congestive heart failure, arrhythmias, or stroke. Sibutramine has been withdrawn from U.S marketplace. The active drug ingredient is not listed on the label for this product.
The products were distributed nationwide via retail stores and internet sales via www.Bestslim.net between April 2013 and July 2013. All lots of the Best Slims 40 pills, Lot # 109400 EXP: Dec. 31, 2016.
CTV Best Group is notifying its customers by US Post Office First-Class mail. Customers with stock of the recalled product should destroy it or return for a refund Consumers who have the recalled product in their possession should stop using the products immediately.
Customers with questions can call (888) 417-2667 Monday through Friday between 10 a.m. and 6p.m. EST for further information. Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using this product.
Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program online, by regular mail, or by fax.
This recall is being conducted with the knowledge of the U.S. Food and Drug Administration.
- Online: www.fda.gov/medwatch/report.htm
- Regular Mail use postage-paid, pre-addressed Form FDA 3500 available at
www.fda gov/MedWatch/getforms.htm Mail to address on the pre-addressed form
- Fax: 1-800-FDA-OIlS
Photo: Product Labels
Recalled Product Photos Are Also Available on FDA's Flickr Photostream.